Search research articles
Contact Us
Filters
Showing results (91-100 of 101) with videos related to
Page
of 11
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 1, 1997
Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies
M B Atkins, M J Robertson, M Gordon, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 7, 2014
PD-L1 expression in nonclear-cell renal cell carcinoma
T K Choueiri, A P Fay, K P Gray, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 5, 2024
Randomized phase II dose comparison LITESPARK-013 study of belzutifan in patients with advanced clear cell renal cell carcinoma
N Agarwal, J Brugarolas, P Ghatalia, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 16, 2001
Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system
C M Balch, S J Soong, J E Gershenwald, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 16, 2001
Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma
C M Balch, A C Buzaid, S J Soong, et al.
Cancer
|
March 16, 2000
A new American Joint Committee on Cancer staging system for cutaneous melanoma
C M Balch, A C Buzaid, M B Atkins, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 28, 2020
Updated efficacy results from the JAVELIN Renal 101 trial: first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma
T K Choueiri, R J Motzer, B I Rini, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 5, 2026
Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: final analysis of efficacy and safety from the phase III CheckMate 214 trial
T K Choueiri, L Albigès, D F McDermott, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 4, 2024
Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 8-year follow-up results of efficacy and safety from the phase III CheckMate 214 trial
N M Tannir, L Albigès, D F McDermott, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 20, 2024
Avelumab + axitinib versus sunitinib as first-line treatment for patients with advanced renal cell carcinoma: final analysis of the phase III JAVELIN Renal 101 trial
T K Choueiri, K Penkov, H Uemura, et al.
Page
of 11
Search research articles
Search
Showing results (91-100 of 101) with videos related to
Sort By:
Page
of 11
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 1, 1997
Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies
M B Atkins, M J Robertson, M Gordon, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 7, 2014
PD-L1 expression in nonclear-cell renal cell carcinoma
T K Choueiri, A P Fay, K P Gray, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 5, 2024
Randomized phase II dose comparison LITESPARK-013 study of belzutifan in patients with advanced clear cell renal cell carcinoma
N Agarwal, J Brugarolas, P Ghatalia, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 16, 2001
Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system
C M Balch, S J Soong, J E Gershenwald, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 16, 2001
Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma
C M Balch, A C Buzaid, S J Soong, et al.
Cancer
|
March 16, 2000
A new American Joint Committee on Cancer staging system for cutaneous melanoma
C M Balch, A C Buzaid, M B Atkins, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 28, 2020
Updated efficacy results from the JAVELIN Renal 101 trial: first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma
T K Choueiri, R J Motzer, B I Rini, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 5, 2026
Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: final analysis of efficacy and safety from the phase III CheckMate 214 trial
T K Choueiri, L Albigès, D F McDermott, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 4, 2024
Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 8-year follow-up results of efficacy and safety from the phase III CheckMate 214 trial
N M Tannir, L Albigès, D F McDermott, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 20, 2024
Avelumab + axitinib versus sunitinib as first-line treatment for patients with advanced renal cell carcinoma: final analysis of the phase III JAVELIN Renal 101 trial
T K Choueiri, K Penkov, H Uemura, et al.
Page
of 11